Skip to Content

Intarcia Patents



One measure of Intarcia’s advances in science, engineering and medicine is apparent from the company’s extensive patent portfolio relating to ITCA 650 (exenatide), implantable osmotic drug delivery device technologies, new chemical entities, pharmaceutical formulations, and various methods of use and manufacture.

As of January 1, 2018, Intarcia’s patent portfolio, providing coverage through various years of expiration, includes approximately 68 issued U.S. utility patents, 23 pending U.S. utility patent applications and 3 pending U.S. design patent applications.  Intarcia’s ex-U.S. patent portfolio includes approximately 350 granted utility patents, 61 pending utility patent applications, 47 registered design patents and 11 pending design patent applications.  

Intarcia continues to support its ongoing scientific discoveries and technical developments with patent filings throughout the world, including Australia, Brazil, Canada, China, Europe, Hong Kong, India, Israel, Japan, Mexico, New Zealand, the Russian Federation, Singapore, South Africa, South Korea and the United States.

Back to top